Axe Compute (AGPU) FY2025 10-K Risk Factors: 19 New, 27 Dropped

What the changes say

Axe Compute abandoned its drug discovery business to adopt an Aethir-focused digital asset treasury and GPU compute strategy.

What changed since the prior 10-K

New

New
We have adopted a digital asset treasury strategy with a focus on ATH, and we may be unable to successfully implement this new strategy
We adopted a digital asset treasury strategy focused on ATH, creating operational, technical, compliance, and security risks.
New
Our shift towards an Aethir-focused strategy requires substantial changes in our day-to-day operations and exposes us to significant operational risks
Our shift to an Aethir-focused strategy exposes us to operational risks, protocol upgrades, and potential illiquidity from staking.
New
The concentration of our ATH holdings enhances the risks inherent in our Aethir-focused strategy
Concentrating our treasury in ATH without diversification magnifies our financial exposure to its price declines, which fell from $0.067072 on September 17, 2025, to $0.004919 on February 6, 2026.
New
The price of ATH is highly volatile and unpredictable, and fluctuations in the price of ATH will directly affect our reported financial results
We account for ATH holdings at fair value under ASU 2023-08, meaning price volatility will directly produce non-cash gains or losses in net income.
New
ATH may have limited liquidity, which could impair our ability to sell ATH holdings at favorable prices or at all, particularly when market conditions are adverse
ATH has limited exchange liquidity and trading volume, and transfer restrictions on our holdings could prevent timely liquidation.
New
The price of ATH is correlated with broader cryptocurrency market conditions and macroeconomic factors outside our control, and adverse developments in the broader digital asset market may disproportionately harm our financial position
ATH prices correlate with broader digital asset market selloffs driven by macroeconomic factors like interest rates and monetary tightening.
New
If the Aethir network is disrupted or encounters any unanticipated difficulties or otherwise does not perform as expected, fails or experiences any other adverse consequences, the value of ATH could be negatively impacted
Aethir network disruptions, outages, or upgrade errors could prevent us from transferring or selling our ATH holdings.
New
ATH and other digital assets are novel assets, and are subject to significant legal, commercial, regulatory and technical uncertainty, which could materially adversely affect the Company ’ s financial position, operations and prospects
Uncertain federal, state, and foreign regulatory interpretations of securities laws could adversely affect ATH and digital assets.
New
In connection with our Treasury Strategy, we expect to interact with various smart contracts deployed on the Aethir network, which may expose us to risks and technical vulnerabilities
Interacting with smart contracts on the Aethir network exposes us to technical vulnerabilities, coding errors, and potential asset loss.
New
Advances in AI model efficiency could reduce demand for GPU compute, adversely affecting the Aethir network and the value of our compute business
Advances in AI model efficiency could reduce raw GPU compute demand, hurting Aethir network utilization and our compute business value.
New
Geopolitical tensions and trade restrictions, particularly between the United States and China, could disrupt GPU supply chains and limit our addressable market
U.S.-China geopolitical tensions and export restrictions on NVIDIA GPUs could disrupt supply chains and limit our compute market.
New
The energy and environmental demands of data centers and GPU compute infrastructure may constrain the growth of the compute market and result in increased regulatory costs or operational limitations
High data center energy consumption, which McKinsey & Company estimates at over 5% of total U.S. energy in 2025, may face regulatory restrictions.
New
Demand for GPU compute is highly concentrated among a small number of large technology companies and governments, and any reduction in their expenditures could have a disproportionate adverse effect on the compute market and our business
New
Our failure to achieve consolidation savings, to incorporate the acquired businesses and assets into our existing operations successfully or to minimize any unforeseen operational difficulties could have a material and adverse effect on our financial condition and results of operations
New
Changes in regulatory interpretations could require us to register as a money services business or money transmitter, leading to increased compliance costs or operational shutdowns
New
The sale of our Legacy Business may not be completed on favorable terms, or at all, which could adversely affect our business and financial condition
New
The Helomics business may experience disruption during the sale process, which could reduce its value and adversely affect our results of operations
New
We may be subject to liabilities, indemnification obligations, or transition costs in connection with the sale of the Helomics business that could adversely affect our financial condition
New
On December 2, 2025, we announced that we received notice from Nasdaq confirming that we had regained compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), allowing our common stock to continue trading on the Nasdaq Capital Market

Dropped

Dropped
Risk Factors Related to the Proposed Acquisition of the Company by Renovaro, Inc
Proposed acquisition by Renovaro, Inc.
Dropped
While the LOI in in effect we are, and once a definitive agreement is in effect we will be, subject to certain restrictions as to the operation of our business
Operating restrictions under the Renovaro LOI and definitive agreement.
Dropped
Risk Factors Related to Our Business
Going concern doubts and $180,426,271 accumulated deficit as of December 31, 2024.
Dropped
The divestiture of our STREAMWAY product line presents risks that could negatively impact our business, financial condition, and results of operations. There is no assurance that we will realize the anticipated benefits of the divestiture consistent with our expectations
Divestiture of the STREAMWAY product line in March 2025.
Dropped
The use of AI in our business is subject to risks associated with new and rapidly evolving technologies and industries, may result in reputational harm or liability, and may not result in the development of commercially viable therapies, drugs or treatments
AI use in cancer drug discovery and biobank of 150,000+ tumor samples.
Dropped
We have entered into, and may enter into additional, collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues
Collaborations, joint ventures, and partnerships for drug development.
Dropped
Our limited operating history with respect to our drug discovery solutions makes evaluation of our business difficult
Limited operating history for drug discovery solutions launched via Helomics.
Dropped
Continue to develop and upgrade our products
Capital investments in early-stage companies for drug discovery.
Dropped
We rely on sole suppliers for some of the materials used in our business, and we may not be able to find replacements or transition to alternative suppliers in a timely manner
Sole suppliers for materials used in our business.
Dropped
If we are sued for product liability or errors and omissions liability, we could face substantial liabilities that exceed our resources
Product liability or errors and omissions liability claims from our products.
Dropped
If our R&D and commercialization efforts for our PEDAL platform take longer than expected, the commercial revenues that use this platform could also be delayed
R&D and commercialization delays for our PEDAL platform.
Dropped
we may not be able to attract and retain the appropriately qualified staff to perform the necessary R&D
Dropped
If demand for our molecular diagnostic tests is unexpectedly high or if we experience problems in scaling our operations, there may be supply interruptions or delays that could limit the growth of our revenue
Dropped
We are dependent on a few key executive officers for our success. Our inability to retain those officers would impede our business plan and growth strategies, which would have a negative impact on our business, financial condition, and results of operations
Dropped
Our business is dependent upon proprietary intellectual property rights, which if we were unable to protect, could have a material adverse effect on our business
Dropped
If we become subject to intellectual property actions, it could hinder our ability to deliver our products and services and our business could be negatively impacted
Dropped
If we breach our license agreements it could have a material adverse effect on our commercialization efforts for our product candidates
Dropped
Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time
Dropped
Changes in patent law, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents
Dropped
We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
Dropped
We may not be able to enforce our intellectual property rights throughout the world
Dropped
Our business is subject to intense governmental regulation and scrutiny, both in the U.S. and abroad
Dropped
If the FDA begins to enforce regulation of our molecular diagnostic tests, we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements
Dropped
If we fail to comply with Federal, State, and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business
Dropped
Complying with numerous statutes and regulations pertaining to our molecular diagnostics business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties
Dropped
If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages
Dropped
The healthcare regulatory and political framework is uncertain and evolving

Reworded

66% rewritten
On April 23, 2023, we effected a 20-for-1 reverse stock split to cure this deficiency. As a result, our stock price increased significantly, and we regained compliance with the Minimum Bid Price Requirement
Updated to reflect that we regained compliance with Nasdaq Minimum Bid Price requirements after trading above $1.00 since January 3, 2025.
44% rewritten
The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and negatively impact the price of our common stock
Updated warrant figures as of December 31, 2025, showing 1,623,179 warrants outstanding at a weighted average exercise price of $17.39 per share.

All 37 risk factors

Headings as the filing states them, in filing order.

Other

01We have adopted a digital asset treasury strategy with a focus on ATH, and we may be unable to successfully implement this new strategyNew
02Our shift towards an Aethir-focused strategy requires substantial changes in our day-to-day operations and exposes us to significant operational risksNew
03The concentration of our ATH holdings enhances the risks inherent in our Aethir-focused strategyNew
04The price of ATH is highly volatile and unpredictable, and fluctuations in the price of ATH will directly affect our reported financial resultsNew
05ATH may have limited liquidity, which could impair our ability to sell ATH holdings at favorable prices or at all, particularly when market conditions are adverseNew
06The price of ATH is correlated with broader cryptocurrency market conditions and macroeconomic factors outside our control, and adverse developments in the broader digital asset market may disproportionately harm our financial positionNew
07If the Aethir network is disrupted or encounters any unanticipated difficulties or otherwise does not perform as expected, fails or experiences any other adverse consequences, the value of ATH could be negatively impactedNew
08ATH and other digital assets are novel assets, and are subject to significant legal, commercial, regulatory and technical uncertainty, which could materially adversely affect the Company ’ s financial position, operations and prospectsNew
09In connection with our Treasury Strategy, we expect to interact with various smart contracts deployed on the Aethir network, which may expose us to risks and technical vulnerabilitiesNew
10Advances in AI model efficiency could reduce demand for GPU compute, adversely affecting the Aethir network and the value of our compute businessNew
11Geopolitical tensions and trade restrictions, particularly between the United States and China, could disrupt GPU supply chains and limit our addressable marketNew
12The energy and environmental demands of data centers and GPU compute infrastructure may constrain the growth of the compute market and result in increased regulatory costs or operational limitationsNew
13Demand for GPU compute is highly concentrated among a small number of large technology companies and governments, and any reduction in their expenditures could have a disproportionate adverse effect on the compute market and our businessNew
14Our failure to achieve consolidation savings, to incorporate the acquired businesses and assets into our existing operations successfully or to minimize any unforeseen operational difficulties could have a material and adverse effect on our financial condition and results of operationsNew
15Changes in regulatory interpretations could require us to register as a money services business or money transmitter, leading to increased compliance costs or operational shutdownsNew
16The sale of our Legacy Business may not be completed on favorable terms, or at all, which could adversely affect our business and financial conditionNew
17The Helomics business may experience disruption during the sale process, which could reduce its value and adversely affect our results of operationsNew
18We may be subject to liabilities, indemnification obligations, or transition costs in connection with the sale of the Helomics business that could adversely affect our financial conditionNew
19Risk Factors Related to the Securities Markets and Ownership of Our Common Stock
20Our common stock could be delisted from the Nasdaq Capital Market, which delisting could hinder your ability to obtain accurate quotations on the price of our common stock or dispose of our common stock in the secondary market
21On April 23, 2023, we effected a 20-for-1 reverse stock split to cure this deficiency. As a result, our stock price increased significantly, and we regained compliance with the Minimum Bid Price Requirement66% rewritten
22On December 2, 2025, we announced that we received notice from Nasdaq confirming that we had regained compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), allowing our common stock to continue trading on the Nasdaq Capital MarketNew
23If we subsequently fail to meet any of the requirements for continued listing on Nasdaq, we could be delisted
24Limitations on director and officer liability and indemnification of our officers and directors by us may discourage stockholders from bringing a suit against a director
25You may experience dilution as a result of future equity offerings
26The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and negatively impact the price of our common stock44% rewritten
27Shares eligible for future sale may adversely affect the market
28We do not expect to pay cash dividends for the foreseeable future, and we may never pay dividends; investors must rely on stock appreciation, if any, for any return on investment in our common stock
29Our board of directors ’ ability to issue undesignated preferred stock and the existence of anti-takeover provisions may depress the value of our common stock
30Our stock price may be volatile, and you could lose all or part of your investment
31Business disruptions could harm our operations, lead to a decline in revenue and increase our costs
32Our success is dependent on our ability to attract and retain technical personnel, sales and marketing personnel, and other skilled management
33Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments is limited by provisions of the Internal Revenue Code and may be subject to further limitation because of prior or future offerings of our stock or other transactions
34Costs incurred because we are a public company may affect our profitability
35Acquisitions involve risks that could result in adverse changes to operating results, cash flows, and liquidity
36the ability to retain or hire qualified personnel required for expanded operations
37If our information technology and communications systems fail or we experience a significant interruption in our operations, our reputation, business, and results of operations could be materially and adversely affected

Other Axe Compute 10-Ks

FY2024 10-K risk factors
45 risks
Axe Compute faces going concern doubts and pending acquisition negotiations with Renovaro, Inc. The company divested its STREAMWAY product line in March 2025 and struggles with Nasdaq minimum bid price compliance.
Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.